Profile data is unavailable for this security.
About the company
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
- Revenue in INR (TTM)34.89bn
- Net income in INR5.10bn
- Incorporated1993
- Employees6.85k
- LocationSyngene International LtdSyngene International Ltd, Biocon Park, SEZ,, Bommasandra IndustrBANGALORE 560099IndiaIND
- Phone+91 8 068918000
- Fax+91 8 068918808
- Websitehttps://www.syngeneintl.com/
More ▼
Mergers & acquisitions
| Acquired company | SYNGENE:NSI since announced | Transaction value |
|---|---|---|
| Stelis Biopharma Ltd-Manufacturing Unit | -11.14% | 75.30m |
Data delayed at least 15 minutes, as of May 06 2024 11:28 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 171.09bn | 1.17k | 46.11 | -- | 40.73 | 14.65 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
| Natco Pharma Ltd. | 38.28bn | 12.78bn | 185.22bn | 3.98k | 14.60 | -- | 12.77 | 4.84 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
| Pfizer Ltd | 22.19bn | 5.02bn | 192.64bn | 1.70k | 38.37 | -- | 33.38 | 8.68 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
| Sanofi India Ltd | 28.51bn | 6.03bn | 198.62bn | 2.17k | 32.94 | 19.56 | 30.91 | 6.97 | 261.78 | 261.78 | 1,237.97 | 440.80 | 1.51 | 2.24 | 21.86 | 13,114,540.00 | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.52 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Piramal Pharma Ltd | 77.82bn | -333.40m | 199.08bn | 6.30k | -- | -- | 28.62 | 2.56 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
| Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 201.34bn | 14.59k | 34.12 | -- | 22.96 | 3.29 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
| Piramal Enterprises Ltd | 79.98bn | -20.16bn | 215.11bn | 12.22k | -- | -- | -- | 2.69 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 241.11bn | 5.75k | 150.62 | 5.86 | 43.62 | 4.78 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Syngene International Ltd | 34.89bn | 5.10bn | 273.08bn | 6.85k | 53.67 | 6.41 | 29.18 | 7.83 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Gland Pharma Ltd | 49.12bn | 6.59bn | 277.78bn | 4.59k | 42.18 | -- | 29.29 | 5.65 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 293.30bn | 5.10k | 57.91 | -- | 45.58 | 8.67 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
| Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 297.23bn | 15.56k | -- | -- | -- | 2.53 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 300.16bn | 7.71k | 36.79 | 8.41 | 31.54 | 7.13 | 64.79 | 64.79 | 334.10 | 283.32 | 0.9034 | 1.30 | 3.65 | -- | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.51 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 15.18 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 71.86bn | 5.64bn | 339.38bn | 16.17k | 60.13 | -- | 36.26 | 4.72 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
| GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 354.96bn | 3.68k | 67.10 | -- | 59.39 | 10.72 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
| Biocon Ltd | 146.13bn | 12.00bn | 365.26bn | 3.41k | 30.43 | -- | 12.12 | 2.50 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
Data as of May 06 2024. Currency figures normalised to Syngene International Ltd's reporting currency: Indian Rupee INR
17.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 24.39m | 6.07% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 7.97m | 1.98% |
| Norges Bank Investment Managementas of 30 Jun 2023 | 7.03m | 1.75% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 5.95m | 1.48% |
| First Sentier Investors (Australia) IM Ltd.as of 31 Dec 2023 | 5.16m | 1.28% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Mar 2024 | 4.88m | 1.21% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023 | 4.01m | 1.00% |
| APG Asset Management NVas of 31 Dec 2022 | 3.47m | 0.86% |
| PGIM India Asset Management Pvt Ltd.as of 31 Mar 2024 | 3.28m | 0.82% |
| Abrdn Asia Ltd.as of 02 May 2024 | 2.81m | 0.70% |
More ▼
Data from 31 Dec 2023 - 15 Apr 2024Source: FactSet Research Systems Inc.
